Inventaire - your friends and communities are your best library

Health-related quality of life results from the phase III CheckMate 067 study.

author

Georgina V. Long

Dirk Schadendorf

1960 -

Vanna Chiarion Sileni

Piotr Rutkowski

1969 -

John Wagstaff

Pier Francesco Ferrucci

Jedd D Wolchok

F Stephen Hodi

Reinhard Dummer

published in: European Journal of Cancer

date of publication: 2017-06-23

main subject: quality of life

Cites articles 23

Date

Title

Authors

2016-10-18

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards

Kim Cocks, Galina Velikova, Francisco Luis Pimentel, Ethan Basch, Melanie Calvert, Andrew Bottomley, Jaap C Reijneveld, Charles S Cleeland, Amylou Dueck, Corneel Coens, Chantal Quinten, Mogens Grønvold, Francesca Martinelli, Carolyn Gotay, Eva Greimel, Jeff A Sloan, Franck Bonnetain, Alicyn Campbell, Laurence Collette, Nancy J Devlin, Hans-Henning Flechtner, Ingolf Griebsch, Paul G Kluetz, Sandra A Mitchell, Carol M Moinpour, Jammbe Z Musoro, Kathy Oliver, Elisabeth Piault-Louis, Christoph Schürmann, Ashley Wilder Smith, Katherine M Soltys, Martin Taphoorn
2016-09-09

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Caroline Robert, Jedd D Wolchok, F Stephen Hodi
2016-09-02

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

Caroline Robert, Dirk Schadendorf, Adil Daud, Antoni Ribas, Axel Hauschild, Jacob Schachter, Christian U Blank, Reinhard Dummer
2016-07-12

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

Caroline Robert, Piotr Rutkowski, Paolo Antonio Ascierto
2016-04-12

Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of missing data

Melanie Bell
2015-05-31

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Jean-Jacques Grob, Piotr Rutkowski, Pier Francesco Ferrucci, Michele Maio, Grant McArthur, Georgina V. Long, John Wagstaff, Lars Bastholt, Dirk Schadendorf, Paolo Antonio Ascierto, Mario Sznol, Jedd D Wolchok, F Stephen Hodi, James Larkin, Reinhard Dummer
2015-05-30

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Richard Sullivan, Urania Dafni, Elisabeth de Vries
2015-04-18

Inclusion of patient-reported outcome measures in registered clinical trials: Evidence from ClinicalTrials.gov (2007-2013)

Karam G Kim
2015-04-20

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Caroline Robert, Jedd D Wolchok, F Stephen Hodi
2015-06-25

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Adil Daud, Christian U Blank
2015-01-22

Nivolumab in previously untreated melanoma without BRAF mutation

Georgina V. Long, Michele Maio, Piotr Rutkowski, Ewa Kalinka-Warzocha, Julie Charles, Vanna Chiarion Sileni, Ana Arance, Paolo Antonio Ascierto
2015-03-17

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.

Filippo de Braud, Jean-Jacques Grob, Igor N. Bondarenko, Ana Arance, Georgina V. Long, Caroline Robert, Daniil Stroyakovskiy, Dirk Schadendorf, Keith Flaherty, Evgeny V Levchenko, Antoni Ribas
2015-10-01

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

Jean-Jacques Grob, Daniil Stroyakovskiy, Kamil Drucis, Vanna Chiarion Sileni, Piotr Rutkowski, Evgeny V Levchenko, Georgina V. Long, Andrzej Mackiewicz, Antoni Ribas, Keith Flaherty, Jacob Schachter, Reinhard Dummer
2013-06-02

Nivolumab plus ipilimumab in advanced melanoma

Mario Sznol, Jedd D Wolchok
2012-06-13

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

Paul Lorigan, Christian H. Ottensmeier
2011-06-05

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Igor N. Bondarenko, Claus Garbe, Jean-Jacques Grob, Michele Maio, Tai-Tsang Chen, Jedd D Wolchok, Michal Lotem
2010-08-19

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Dirk Schadendorf, Paul Lorigan, Christian H. Ottensmeier, Caroline Robert, Jedd D Wolchok, F Stephen Hodi
2007-12-21

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer.

David Cella
2001-03-05

Medscape's response to the Institute of Medicine Report: Crossing the quality chasm: a new health system for the 21st century
1998-01-01

Interpreting the significance of changes in health-related quality-of-life scores.

Benny Chung-Ying Zee
1993-03-03

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
1993-11-01

The validity and reproducibility of a work productivity and activity impairment instrument
1990-12

EuroQol--a new facility for the measurement of health-related quality of life

Article - wd:Q47147156

Welcome to Inventaire

the library of your friends and communities

learn more